高危前列腺癌根治术后辅助放疗对比早期挽救放疗与死亡风险
该研究评估了前列腺癌根治术后辅助放疗对比早期挽救放疗对不良病理(pN1或Gleason 8-10且pT3/4)患者全因死亡风险的影响。中位随访8.16年,共26118例患者,2104例死亡。结论认为pN1或Gleason 8-10且pT3/4患者可考虑辅助放疗。
要点
- 高危不良病理(pN1或Gleason 8-10且pT3/4)前列腺癌根治术后,辅助放疗可能降低全因死亡风险。
- 排除持续PSA阳性者后,辅助对比早期挽救放疗的HR在排除pN1时为0.33,包括pN1时为0.66。
- 临床应考虑对pN1或Gleason 8-10且pT3/4患者行辅助放疗。
核心结论
- 对于pN1或Gleason评分8-10且pT3/4的前列腺癌根治术后患者,辅助放疗对比早期挽救放疗与显著降低的全因死亡风险相关。
研究设计与样本
- 回顾性队列研究,纳入26118例前列腺癌根治术后患者,中位随访8.16年(IQR 6.00-12.10)。
- 使用倾向性评分估计辅助对比早期挽救放疗对全因死亡风险的因果效应,并调整年龄、预后因素、部位及时间依赖性ADT使用。
主要发现
- 随访期间2104例(8.06%)死亡,其中539例(25.62%)死于前列腺癌。
关键数值与推荐
- 不良病理定义为阳性盆腔淋巴结(pN1)或Gleason评分8-10且疾病超出前列腺(pT3/4)。
临床怎么用
- 对于pN1或Gleason评分8-10且pT3/4的前列腺癌根治术后患者,应考虑辅助放疗以降低全因死亡风险。
局限性
- 研究为回顾性设计,尽管使用倾向性评分,仍可能存在未测量的混杂因素。
- 随机对照试验中不良病理患者代表性不足且可能存在永生时间偏倚,本研究结果需在更广泛人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant compared with early salvage radiation therapy (sRT) following radical prostatectomy (RP) has not been shown to reduce progression-free survival in randomized controlled trials. However, these trials might have missed a benefit in men with adverse pathology at RP given that these men were under-represented and immortal time bias might have been present; herein, we investigate this possibility. METHODS: We evaluated the impact of adjuvant versus early sRT on all-cause mortality (ACM) risk in men with adverse pathology defined as positive pelvic lymph nodes (pN1) or pGleason score 8-10 prostate cancer (PC) and disease extending beyond the prostate (pT3/4). We used a treatment propensity score to minimize potential treatment selection bias when estimating the causal effect of adjuvant versus early sRT on ACM risk and a sensitivity analysis to assess the impact that varying definitions of adverse pathology had on ACM risk adjusting for age at RP, PC prognostic factors, site, and the time-dependent use of post-RP androgen deprivation therapy. RESULTS: After a median follow-up (interquartile range) of 8.16 (6.00-12.10) years, of the 26,118 men in the study cohort, 2,104 (8.06%) died, of which 539 (25.62%) were from PC. After excluding men with a persistent prostate-specific antigen, adjuvant compared with early sRT was associated with a significantly lower ACM risk among men with adverse pathology at RP when men with pN1 PC were excluded (0.33 [0.13-0.85]; P = .02) or included (0.66 [0.44-0.99]; P = .04). CONCLUSION: Adjuvant radiation therapy should be considered in men with pN1 or pGleason score 8 to 10 and pT3/4 PC given the possibility that a significant reduction in ACM risk exists.
引用
- Tilki D, Chen MH, Wu J, et al. Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2021. PMID: 34086480. doi:10.1200/JCO.20.03714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。